全球细胞生物学研究市场（2024-2030）

单细胞技术和基因组学工具的进步推动了细胞生物学研究的变革性成长

本报告研究了全球细胞生物学研究市场，预计该市场将在2024年至2030年间实现高速成长，并取得显着的收益里程碑。这一增长反映了仪器、耗材和软体平台技术创新的加速，并受到数据驱动的研究模式、日益增多的学术界与生物製药公司的合作以及数位化实验室工作流程的推动。此外，新型细胞治疗方法的出现以及生物学研究日益复杂的发展，对更先进的工具和工作流程提出了更高的要求。

该分析包括：

• 推动和限制细胞生物学研究解决方案采用的因素
• 按产品类型（仪器、消耗品和试剂、软体）、最终用途（製药、学术和研究、临床实验室）、技术（单细胞分析、活细胞成像、高通量筛检、流式细胞技术、细胞培养、CRISPR 和基因编辑、其他）和地区（北美、欧洲、亚太、拉丁美洲、中东和非洲）细分
• 各产品领域和技术领域的知名公司

它还透过评估行业细分、新兴经营模式、收益和预测来确定细胞生物学研究领域的关键成长机会。

研究期间为2024年至2030年，以2024年为基准年，2025年至2030年为预测期间。

收益及预测

预计 2024 年营收将达到 199.4 亿美元，2024-2030 年期间的复合年增长率为 7.5%。

分析范围

• 该分析考察了全球细胞生物学研究市场，其中包括分析样本中的细胞以研究其结构、功能和行为。
• 对细胞生物学研究市场的关注是由快速的技术进步和对提高研究效率和可重复性的创新解决方案日益增长的需求所驱动的。
• 细胞生物学研究涵盖广泛的技术和方法，包括细胞培养、成像、单细胞分析和多组体学方法。这些领域的发展正在推动疾病机制、再生医学和生物製药领域的探索。
• 细胞生物学领域的关键创新包括高通量筛检(HTS)、先进成像技术和人工智慧驱动的数据分析的整合。这些发展使研究人员能够更深入地了解细胞过程，从而改善药物发现和治疗策略。
• 市场可细分为解决方案、应用和产品/服务。本研究重点关注细胞生物学领域的新兴技术和研究工具，以进行收益估算和预测分析。
• 区域细分仅依产品类型进行。

三大战略要务对细胞生物学研究产业的影响

颠覆性技术

• 单细胞RNA测序、CRISPR基因编辑、空间转录组学和AI驱动的图像分析等新兴技术正在重塑细胞生物学研究。这些创新使我们能够更详细、即时地了解细胞功能，为疾病建模、再生医学和药物研发领域的突破奠定基础。
• 製造商和研究供应商正在投资可扩展且易于使用的工具，这些工具集自动化、多组体学功能和即时分析于一体。人们越来越重视整合仪器、软体和人工智慧演算法的系统，以简化细胞工作流程并提供可操作的洞察。新兴企业和成熟的供应商都越来越注重灵活性、模组化和可自订性，以满足不断变化的研究需求。

变革大趋势

• 人口老化、慢性疾病、新兴流行病以及个人化医疗的转变等全球性挑战，正在推动对更深入的细胞洞察的需求。随着研究人员试图理解更复杂生理环境下的细胞行为，人们对类器官、3D细胞培养物和原代细胞的兴趣日益浓厚。
• 市场相关人员正在调整其研发策略，以应对公共卫生优先事项和全球研究挑战。对弥合基础科学与临床应用之间差距的转化研究工具的需求正在快速增长。这些大趋势正在推动对细胞化验分析和高内涵筛检(HCS) 平台的长期投资。

产业融合

• 细胞生物学与资料科学、微流体、材料科学和机器人技术的交叉日益紧密。这种跨学科合作正在推动结合自动化细胞处理、高通量筛选和高级分析技术的下一代平台的开发。这种融合正在加快发现的步伐，同时减少差异性和人为错误。
• 主要企业正在与高科技公司和学术机构合作，开发可互通的智慧实验室解决方案。整合云端运算、机器学习和实验室自动化的平台正成为现代细胞生物学实验室不可或缺的一部分，从而催生新的市场和使用案例，尤其是在药物研发、合成生物学和精准医疗领域。

主要竞争对手

影像技术

• Revvity
• Zeiss Microscopy
• Nikon Instruments Inc.
• Leica Microsystems
• Evident Scientific
• Bruker Corporation
• JEOL Ltd.
• Hitachi High-Tech Corporation
• PerkinElmer Inc.
• Molecular Devices LLC
• GE Healthcare Life Sciences
• Yokogawa Electric Corporation
• Amnis Corporation (part of Luminex Corporation)
• Cytek(R)
• Chemometec A/S

流式细胞仪技术

• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Miltenyi Biotec
• Sony Biotechnology Inc.
• Fluidigm Corporation
• Amnis 公司（Luminex 公司的一部分）
• Nexcleom Bioscience LLC
• Chemometec A/S

细胞培养技术

• Corning Incorporated
• Greiner Bio-One International GmbH
• Thermo Fisher Scientific
• Lonza Group
• InSphero AG
• Kuraray Co., Ltd.
• Sartorius AG
• Eppendorf AG
• Appilkon Biotechnology (part of Getinge)
• Merck KGaA
• GE Healthcare Life Sciences
• Cellares
• CellulaRevolution
• TissenBioFarm
• Scinobuh Biotech

细胞分离技术

• Miltenyi Biotec
• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Fluidigm Corporation
• Dolomite Microfluidics

驱动程式

• 研究技术的进步，尤其是 CRISPR/Cas9、基因编辑和新一代定序 (NGS)，正在彻底改变研究能力，实现精准基因编辑和快速基因序列测定，并推动基因治疗和肿瘤学领域的创新。这些技术使研究人员能够精准编辑基因，拓展研究机会，加速肿瘤学、遗传学和个人化医疗领域的发现。人工智慧和自动化技术的不断发展与整合，也正在提高实验室流程的效率和可重复性。
• 个人化医疗和再生医学的需求正促使人们更加重视细胞疗法，包括干细胞疗法和基因改造免疫细胞。各大公司正致力于开发干细胞等细胞疗法解决方案，干细胞在再生医学中正变得至关重要，可用于治疗阿兹海默症、糖尿病和心臟病等疾病。
• 全球癌症、糖尿病和心血管疾病等慢性疾病的增多，推动了对更先进研究工具和解决方案的需求，从而增加了再生医学和基因治疗等领域的资金投入和创新，重点关注个性化治疗方案，以更有效地管理这些疾病。
• 学术机构、生物技术公司和製药公司之间的策略伙伴关係正在推动细胞生物学研究市场的成长。这些合作共用专业知识、资源和资金，加快了创新步伐，并促进了新治疗方法和研究工具的开发。
• 市场成长受到监管环境变化的推动，尤其是在基因编辑和干细胞治疗领域。政府和监管机构对生物技术、临床试验和产品核可的支持正在增加，这表明研究和商业化的法规环境更加有利，从而刺激了细胞生物学研究的创新。

成长限制因素

• 基因编辑平台和高通量定序系统等先进细胞生物学研究工具和技术的高昂研发成本仍是一大障碍。研究机构和生技公司面临高昂的初始投资，这阻碍了创新，也使得预算有限的小型机构和实验室难以负担这些技术。
• 在全球范围内，CRISPR/Cas9、NGS 和 PCR 等先进细胞生物学研究技术的专业人才短缺。专业的培训和教育课程对于满足日益增长的人才需求至关重要。缺乏经过充分培训的人才可能会阻碍这些技术的普及和有效使用。
• 儘管技术进步日新月异，但工具的复杂性以及在准确性、可重复性和可扩展性方面的技术限制仍然存在。 NGS 资料的解读和基因编辑效率的挑战仍有待解决。
• 随着越来越多的细胞生物学研究使用患者基因数据和敏感的生物信息，数据隐私和安​​全审查方面的担忧日益凸显。 《一般资料保护规范》（GDPR）等日益严格的资料保护条例，为管理大型资料集的公司和研究机构带来了挑战。安全漏洞可能会削弱人们对该技术的信任，并减缓市场成长。

目录

调查范围

成长环境：细胞生物学研究市场的转型

• 为什么成长变得越来越困难
• 策略要务
• 三大策略要务对细胞生物学研究产业的影响

细胞生物学研究市场生态系统

• 竞争环境
• 主要竞争对手

细胞生物学研究市场的成长动力

• 成长指标
• 成长动力
• 成长限制因素
• 预测考虑因素
• 收益预测
• 按产品分類的收益预测
• 按最终用户预测收益
• 按技术分類的收益预测
• 各地区收益预测
• 收益预测分析
• 按产品分類的收益预测分析
• 按最终用户的收益预测分析
• 按技术分類的收益预测分析
• 各地区收益预测分析
• 价格趋势及预测分析
• 收益分享
• 公司矩阵
• 企业投资组合
• 收益份额分析

特色公司：单细胞分析

• 特色公司：活细胞成像
• 特色公司：高通量筛检
• 特色公司：流式细胞技术
• 特色公司：细胞培养
• 焦点公司：CRISPR 与基因编辑
• 特色公司：其他

成长动力：设备

• 成长指标
• 收益预测
• 各地区收益预测
• 预测分析

成长动力：消耗品和试剂

• 成长指标
• 收益预测
• 各地区收益预测
• 预测分析

成长动力：软体

• 成长指标
• 收益预测
• 各地区收益预测
• 预测分析

细胞生物学研究市场的成长机会

• 成长机会 1：创建用于工作流程整合的软体解决方案
• 成长机会2：将单细胞分析与基因体学及基因编辑工具结合
• 成长机会3：为生物製药和转化研究开发客製化解决方案

附录与后续步骤

Cell Biology Research is Experiencing Transformational Growth due to Advances in Single-Cell Technologies and Genomics Tools

In the study, Frost & Sullivan examines the global cell biology research market. The market is projected to register high growth between 2024 and 2030, reaching significant revenue milestones. This growth reflects accelerating innovation across instrumentation, consumables, and software platforms, with a firm push from data-driven research models, increased academic and biopharma collaboration, and the digitalization of lab workflows. In addition, the emergence of new cell-based therapies and the increasing complexity of biological research call for more sophisticated tools and workflows.

This analysis includes:

• Factors driving and restraining the adoption of cell biology research solutions
• Segmentation by product type (instruments, consumables and reagents, software), end use (pharma, academia and research, clinical labs), technology (single-cell analysis, live-cell imaging, high-throughput screening, flow cytometry, cell culture, CRISPR and gene editing, others), and region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa)
• Notable companies in each product segment and technology

Frost & Sullivan also identifies the major growth opportunities in the cell biology research space by evaluating the industry segments, emerging business models, and revenues and forecasts.

The study period is 2024-2030, with 2024 as the base year and 2025-2030 as the forecast period.

Revenue Forecast

The revenue estimate for the base year 2024 is $19.94 billion, with a CAGR of 7.5% for the study period 2024-2030.

Scope of Analysis

• This analysis examines the global cell biology research market, which involves analyzing cells from a sample to study their structure, function, and behavior.
• Frost & Sullivan has focused on the cell biology research market due to its rapid advancements in technology and increasing demand for innovative solutions that enhance research efficiency and reproducibility.
• Cell biology research encompasses a wide range of techniques and technologies, including cell culture, imaging, single-cell analysis, and multomics approaches. Advances in these areas are driving discoveries in disease mechanisms, regenerative medicine, and biopharmaceutical development.
• Key innovations in cell biology include the integration of high-throughput screening (HTS), advanced imaging techniques, and AI-driven data analysis. These developments enable researchers to gain deeper insights into cellular processes, improving drug discovery and therapeutic strategies.
• The market can be categorized into solutions, applications, and product and service offerings. This study focuses on emerging technologies and research tools within cell biology for revenue estimation and forecast analysis.
• The regional breakdown is only provided for the product type segment.

The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Disruptive Technologies

• Why: Emerging technologies such as single-cell RNA sequencing, CRISPR gene editing, spatial transcriptomics, and AI-powered image analysis are reshaping cell biology research. These innovations enable a more detailed, real-time, and functional understanding of cells, supporting breakthroughs in disease modeling, regenerative medicine, and drug discovery.
• Frost Perspective: Manufacturers and research suppliers are investing in scalable, user-friendly tools that combine automation, multiomics capabilities, and real-time analytics. There is growing emphasis on systems that integrate instruments, software, and AI algorithms to streamline cellular workflows and deliver actionable insights. Start-ups and larger vendors alike increasingly focus on flexibility, modularity, and customization to meet evolving research needs.

Transformative Megatrends

• Why: Global challenges, including an aging population, chronic disease burden, emerging pandemics, and the shift toward personalized medicine, are driving demand for deeper cellular insights. As researchers seek to understand cell behavior in more complex physiological contexts, interest in organoids, 3D cell cultures, and primary cells has surged.
• Frost Perspective: Market players are aligning their R&D strategies with public health priorities and global research agendas. The demand for translational research tools that bridge basic science and clinical application is growing fast. These megatrends are fueling long-term investment in cell-based assays and high-content screening (HCS) platforms.

Industry Convergence

• Why: Cell biology increasingly intersects with data science, microfluidics, materials science, and robotics. These cross-industry collaborations are driving the development of next-gen platforms that combine automated cell handling, HTS, and advanced analytics. This convergence is accelerating the pace of discovery while reducing variability and manual errors.
• Frost Perspective: Leading vendors are partnering with tech companies and academic institutions to develop interoperable, smart lab solutions. Platforms that integrate cloud computing, machine learning, and lab automation are becoming essential for modern cell biology labs. This is opening new markets and use cases, particularly in pharma R&D, synthetic biology, and precision medicine.

Key Competitors

Imaging Technologies

• Revvity
• Zeiss Microscopy
• Nikon Instruments Inc.
• Leica Microsystems
• Evident Scientific
• Bruker Corporation
• JEOL Ltd.
• Hitachi High-Tech Corporation
• PerkinElmer Inc.
• Molecular Devices LLC
• GE Healthcare Life Sciences
• Yokogawa Electric Corporation
• Amnis Corporation (part of Luminex Corporation)
• Cytek(R)
• Chemometec A/S

Cytometric Technologies

• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Miltenyi Biotec
• Sony Biotechnology Inc.
• Fluidigm Corporation
• Amnis Corporation (part of Luminex Corporation)
• Nexcleom Bioscience LLC
• Chemometec A/S

Cell Culture Technologies

• Corning Incorporated
• Greiner Bio-One International GmbH
• Thermo Fisher Scientific
• Lonza Group
• InSphero AG
• Kuraray Co., Ltd.
• Sartorius AG
• Eppendorf AG
• Appilkon Biotechnology (part of Getinge)
• Merck KGaA
• GE Healthcare Life Sciences
• Cellares
• CellulaRevolution
• TissenBioFarm
• Scinobuh Biotech

Cell Separation Technologies

• Miltenyi Biotec
• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Fluidigm Corporation
• Dolomite Microfluidics

Growth Drivers

• Advances in research technologies, particularly in CRISPR/Cas9, gene editing, and NGS, are revolutionizing research capabilities, enabling precision gene editing and rapid genetic sequencing, and driving innovation in gene therapy and oncology. These technologies allow researchers to edit genes precisely, expand study areas, and accelerate discoveries in oncology, genetics, and personalized medicine. The continued development and integration of AI and automation are also improving efficiency and reproducibility in lab processes.
• Demand for personalized therapies and regenerative medicine is leading to greater emphasis on cell-based therapies, including stem cell therapies and gene-modified immune cells. Companies are focusing on the development of cell therapy solutions, such as stem cells, which are becoming pivotal in regenerative medicine in treating diseases like Alzheimer's, diabetes, and heart disease.
• The global rise in chronic diseases, including cancer, diabetes, and cardiovascular diseases, is driving demand for more advanced research tools and solutions. This has led to increased funding and innovation in fields like regenerative medicine and gene therapy, with a focus on personalized treatment options to manage these conditions more effectively.
• Strategic partnerships between academic institutions, biotech firms, and pharmaceutical companies are key drivers of growth in the Cell Biology Research Market. These collaborations enable the pooling of expertise, resources, and funding, accelerating the pace of innovation and facilitating the development of new therapies and research tools.
• The evolving regulatory landscape, particularly for gene editing and stem cell therapies, is facilitating market growth. Government and regulatory bodies' support for biotechnology, clinical trials, and product approvals is strengthening. This signals a regulatory environment conducive to research and commercialization and encourages innovation in the field of cell biology research.

Growth Restraints

• The high R&D cost of advanced cell biology research tools and technologies, such as gene editing platforms and high-throughput sequencing systems, remains a significant barrier. Research institutions and biotech companies face high initial investments, which can slow down innovation. It also hinders the affordability of these technologies for smaller organizations or labs with limited budgets.
• There is a global shortage of skilled professionals capable of working with advanced cell biology research technologies, such as CRISPR/Cas9, NGS, and PCR. Specialized training and education programs to meet the increasing demand for qualified personnel are critical. Without an adequately trained workforce, the adoption and effective use of these technologies can be hindered.
• Complexity and technical limitations of tools in terms of precision, reproducibility, and scalability still occur despite rapid technological advancements. Challenges in data interpretation from NGS or the efficiency of gene editing still need to be addressed.
• Concerns regarding data privacy and security have become more prominent as more cell biology research is conducted using patient genetic data and sensitive biological information. Stricter data protection regulations, such as GDPR, pose challenges for companies and research institutions managing large datasets. Any breaches in security could undermine trust in the technologies and slow market growth.

Table of Contents

Research Scope

• Scope of Analysis
• Segmentation

Growth Environment: Transformation in the Cell Biology Research Market

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Ecosystem in the Cell Biology Research Market

• Competitive Environment
• Key Competitors

Growth Generator in the Cell Biology Research Market

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast by Product
• Revenue Forecast by End User
• Revenue Forecast by Technology
• Revenue Forecast by Region
• Revenue Forecast Analysis
• Revenue Forecast Analysis by Product
• Revenue Forecast Analysis by End User
• Revenue Forecast Analysis by Technology
• Revenue Forecast Analysis by Region
• Pricing Trends and Forecast Analysis
• Revenue Share
• Company Matrix
• Company Portfolio
• Revenue Share Analysis

Companies to Watch: Single-Cell Analysis

• Companies to Watch: Live-Cell Imaging
• Companies to Watch: High-Throughput Screening
• Companies to Watch: Flow Cytometry
• Companies to Watch: Cell Culture
• Companies to Watch: CRISPR and Gene Editing
• Companies to Watch: Others*

Growth Generator: Instruments

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Generator: Consumables and Reagents

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Generator: Software

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Opportunity Universe in the Cell Biology Research Market

• Growth Opportunity 1: Create Software Solutions for Workflow Integration
• Growth Opportunity 2: Combine Single-Cell Analysis with Genomics and Gene Editing Tools
• Growth Opportunity 3: Develop Custom Solutions for Biopharma and Translational Research

Appendix & Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer